Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel -

- Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort -

ORLANDO, Fla. and TUSTIN, Calif., June 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that preliminary results from a Phase II trial of its lead anti-phosphatidylserine antibody bavituximab in combination with docetaxel in patients with advanced breast cancer will be discussed this morning in an oral presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Initial data from the Phase II study indicates that 10 of 14 evaluable patients in the first cohort of the trial achieved an objective tumor response by the end of the treatment period according to RECIST criteria. Recent analysis shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months.

Bavituximab is a monoclonal antibody with a unique anti-cancer mechanism that works by helping to activate the body's own immune system to fight cancer. Bavituximab binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed specifically on the outside of cells that line tumor blood vessels. Once bound to the exposed PS, bavituximab helps mobilize the body's immune system to destroy both the tumors and their associated blood vessels.

"The preliminary data in this first cohort of advanced breast cancer patients treated with bavituximab and docetaxel along with data we have generated from the two other ongoing Phase II bavituximab cancer trials is very encouraging and suggests that bavituxi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
(Date:12/19/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... privately held company based in Redwood ... big data platform for centralized management and processing ... on-market Genomic Management Solution, Bina-GMS 1 , empowers ... and scalable analyses to maximize the value of ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... PharmSource Lead Sheet upgrades database resources to help companies serving ... , ... Springfield, VA (PRWEB) November ... Information Services, Inc. (PharmSource) announces the expansion of its PharmSource ...
... quantum computing is that it will dramatically outshine traditional ... factoring large numbers, creating uncrackable codes and simulating the ... that direction, if you,ll pardon the pun, has been ... a paper published in the journal Nature . ...
... ARBOR, Mich., Nov. 21 MichBio, the association ... service providers to its fourth annual Expo on ... Financial ShowPlace in Novi, MI. The MichBio ... industry professionals.,In addition, this year,s event attracted 56 ...
Cached Biology Technology:PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma 2Stanford: Quantum computing spins closer 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... dip in the ocean, nuclear fuel is probably the farthest thing ... of just 3 parts per billion, but it adds up. Combined, ... enough to potentially fuel the worlds nuclear power plantsfor 6,500 years., ... source since the 1960s, but previous approaches have been too expensive ...
... have discovered a biological explanation for why low levels ... why breathing treatments help SMA patients live longer. The ... SMA is a progressive neurodegenerative disease that causes muscle ... one of the most common treatment options for severe ...
... scientist Chittaranjan Kole was awarded the Outstanding Crop Scientist ... was one of three scientists to receive the award ... field of crop science. He also chaired a special ... month, "Genomics and Breeding of Climate Resilient Crops ...
Cached Biology News:Low oxygen levels may decrease life-saving protein in spinal muscular atrophy 2
... of the Axima range, the AXIMA-CFR ... accuracy, resolution, sensitivity and mass range, ... linear and reflectron time-of-flight analysis. The ... the generation of seamless PSD, providing ...
... new MALDI O-TOF creates a new category ... orthogonal platform that has been licensed to ... of Manitoba. , As the first single ... and collisional cooling, the prOTOF 2000 represents ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
Biology Products: